CEPI, Austrian Biotech Company Themis Sign Agreement To Develop Vaccines For MERS, Lassa Fever

STAT: Global health coalition inks agreement to develop vaccines for MERS, Lassa fever
“…In a major step, that organization known as CEPI — the Coalition for Epidemic Preparedness Innovations — said this week that it has awarded its first contract, an agreement with an Austrian biotech company to develop vaccines to protect against Middle East respiratory syndrome, or MERS, and Lassa fever. Themis Bioscience, of Vienna, could receive up to $37.5 million to develop and manufacture the vaccines. The privately held company already has Zika and chikungunya virus vaccines in its development pipeline…” (Branswell, 3/6).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.